Skip to main content

Abiomed Value Stock - Dividend - Research Selection


ISIN: US0036541003, WKN: 873886

Market price date: 19.05.2022
Market price: 238,65 USD

Abiomed Fundamental data and company key figures of the share

Annual reports in USD
Key figures 23-05-2021
Cash flow
Net operating cash flow 274.578.000
Capital Expenditures -53.383.000
Free cash flow 221.195.008
Balance sheet
Total Equity 1.503.330.000
Liabilities & Shareholders equity 1.673.390.000
Income statement
Net income 136.505.000
Eps (diluted) 4,940
Diluted shares outstanding 45.674.000
Net sales/revenue 1.031.750.000

Fundamental ratios calculated on: 19-05-2022

Key figures 19-05-2022
Cash flow
P/C 39,70
P/FC 49,28
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization10.900.100.096,00 USD
CountryUnited States
IndicesNASDAQ Comp.,Russell 3000,S&P 500,MSCI World Index
SectorsHealth Care Equipment
Raw Data SourceUS GAAP in Millionen USD
Stock Split2000-10-03,2.0000/1.0000; 2000-10-02,2.0000/1.0000

Description of the company

ABIOMED, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. In September 2012, the Company announced that its Impella CP product received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for partial circulatory support for up to six hours.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

DANVERS, Mass., May 18, 2022--Abiomed will feature the most recent Impella research, technological advances aimed at improving AMICS patient outcomes at SCAI Scientific Sessions.

Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cable companies to offer effectively free internet to low-income homes

The news means that tens of millions of households could receive high-speed internet at no cost, according to the White House.

Should Weakness in Abiomed, Inc.'s (NASDAQ:ABMD) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

It is hard to get excited after looking at Abiomed's (NASDAQ:ABMD) recent performance, when its stock has declined 19...

Abiomed Inc. stock underperforms Friday when compared to competitors

Shares of Abiomed Inc. shed 5.40% to $257.54 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

Abiomed Inc. stock underperforms Thursday when compared to competitors

Shares of Abiomed Inc. shed 7.78% to $272.25 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...

Abiomed Inc. stock outperforms competitors on strong trading day

Shares of Abiomed Inc. advanced 3.27% to $295.21 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...

Abiomed Inc. stock rises Tuesday, still underperforms market

Shares of Abiomed Inc. inched 0.06% higher to $285.87 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...